Roche's Promising Weight Loss Pill Hits Eli Lilly, Novo Nordisk Shares
TL;DR Summary
Eli Lilly and Novo Nordisk stocks fell after Roche's Genentech unit reported positive early-stage data for its oral weight-loss drug, CT-996, which led to 6% weight loss in four weeks. This new development poses competition to Eli Lilly and Novo Nordisk's injectable treatments. Viking Therapeutics and Amgen, also developing oral weight-loss drugs, saw their stocks decline as well.
- Eli Lilly, Novo Nordisk Fall On Rival's Obesity Drug Investor's Business Daily
- Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche CNBC
- Roche Climbs As Once-Daily Weight Loss Pill Shows Promise Forbes
- Roche’s $2.7B weight-loss wager delivers early oral GLP-1 win Fierce Biotech
- Roche’s Oral Weight Loss Drug Shows Promise in Early Study Bloomberg
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
74%
226 → 58 words
Want the full story? Read the original article
Read on Investor's Business Daily